HC Wainwright & Co. analyst Robert Burns reiterates Viracta Therapeutics (NASDAQ:VIRX) with a Buy and maintains $4 price target.
- Headlines
- HC Wainwright & Co. Reiterates Buy on Viracta Therapeutics, Maintains $4 Price Target
HC Wainwright & Co. Reiterates Buy on Viracta Therapeutics, Maintains $4 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Related Stocks Related Stocks
Symbol Mini Chart Latest Price
Unlock the Full List
Latest
16:59
Guangdong will add another international airport, which will become one of the three major international airports in Guangdong Province.
16:44
Guangzhou Tinci Materials Technology plans to repurchase company shares for 0.1 billion yuan to -0.2 billion yuan.
Guangzhou Tinci Materials Technology-3.55%
16:25
The takeoff and landing restrictions at airports such as Kazan have been lifted.